A high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent
about
Pre-Clinical Models of Diffuse Intrinsic Pontine GliomaPre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma ModelsPolo-like Kinase 1 as a potential therapeutic target in Diffuse Intrinsic Pontine GliomaDevelopment of a DIPG Orthotopic Model in Mice Using an Implantable Guide-Screw System.Repurposing the anti-epileptic drug sodium valproate as an adjuvant treatment for diffuse intrinsic pontine glioma.Tumor location, but not H3.3K27M, significantly influences the blood-brain-barrier permeability in a genetic mouse model of pediatric high-grade gliomaABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B-Driven Brainstem Glioma Model.IGF-binding protein 2 is a candidate target of therapeutic potential in cancer.The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma.Advances in drug delivery to high grade gliomas.In vivo evaluation of IGF1R/IR PET ligand [18F]BMS-754807 in rodents.High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth.Potential New Therapies for Pediatric Diffuse Intrinsic Pontine Glioma.Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma.Diffuse Intrinsic Pontine Glioma : Clinical Features, Molecular Genetics, and Novel Targeted Therapeutics.
P2860
Q26799976-CED1B4FD-26D9-4353-B14B-D134A6544669Q28468398-329C0A96-126B-45B2-A81F-BC8FC93E8CAEQ36107521-E6BD6671-8792-49C0-BA60-0842D1D65E81Q36255670-D831607D-178A-4E7D-80A8-C7124CAB20F5Q36380213-D68B968D-459F-42F5-B9D6-E07E3A4124D0Q36484037-2FE081E4-B6A3-4BC9-B072-077D2ACB5F29Q36918220-4F04F3BE-2EAF-42F4-939E-DF9ABC0080E0Q38667847-EA8DA5E0-EE6A-4C01-BEA2-75CB719F0528Q38705818-06ABF238-19C5-49BC-B027-1C14560AE07BQ38917630-F914EB65-C32F-4C11-9998-54A287246E3FQ39017291-17DAAEC1-EA39-4582-962C-C384CF2392E5Q41026125-A7ADB2C5-BF03-4D8F-AFC5-335BE5E7E593Q41109977-02C36771-93D3-49AE-BB5F-7F74E418E7E2Q47587376-AE4A50A0-905A-415B-AA99-030F4729BFF4Q55285428-D78167DD-CD1A-4DF5-B5E8-B07E1190C794
P2860
A high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
A high-throughput in vitro dru ...... a promising therapeutic agent
@ast
A high-throughput in vitro dru ...... a promising therapeutic agent
@en
A high-throughput in vitro dru ...... a promising therapeutic agent
@nl
type
label
A high-throughput in vitro dru ...... a promising therapeutic agent
@ast
A high-throughput in vitro dru ...... a promising therapeutic agent
@en
A high-throughput in vitro dru ...... a promising therapeutic agent
@nl
prefLabel
A high-throughput in vitro dru ...... a promising therapeutic agent
@ast
A high-throughput in vitro dru ...... a promising therapeutic agent
@en
A high-throughput in vitro dru ...... a promising therapeutic agent
@nl
P2093
P2860
P3181
P1433
P1476
A high-throughput in vitro dru ...... a promising therapeutic agent
@en
P2093
Alex Chung
Christine Hoeman
Donna M Crabtree
Francisco J Cordero
Ivan Spasojevic
Katherine L Misuraca
Kelly L Barton
Kristin Schroeder
Kyle G Halvorson
Noah Berlow
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0118926
P407
P577
2015-01-01T00:00:00Z